Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
NCT ID: NCT01350648
Last Updated: 2024-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
569 participants
OBSERVATIONAL
2011-08-23
2022-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who have hepatitis B or hepatitis C. The purpose is to understand more about how these viruses affect the immune system over the long term (up to 10 years). The study will also compare how these viruses affect people who do and do not have HIV, the virus that causes AIDS.
Objectives:
* To do a long-term study of hepatitis B and hepatitis C infection.
* To study the effects of hepatitis B and hepatitis C infection in people do and do not have HIV.
Eligibility:
\- People at least 18 years of age who have hepatitis B or hepatitis C and have a regular doctor for their medical care.
Design:
* Participants will be screened with a physical exam and medical history. Those who do not have a regular doctor to provide medical care during the study will not be able to take part.
* Participants will have yearly visits with study researchers for up to 10 years. These tests will be done at each visit.
* Medical history and physical exam.
* Questionnaire (optional) on emotions, sexual behaviors, use of alcohol and drugs, and quality of life.
* Blood and urine tests, including HIV testing.
* Tissue sample collections for those who have had a liver or other tissue biopsy.
* Participants may leave the study at any time. They will receive the standard of care from their regular doctor throughout the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
NCT00004850
"Real-life" Cohort of Patients With Chronic Hepatitis B Virus Infection
NCT01732081
HBV-HIV Coinfection Research Network
NCT01924455
History of Hepatitis C in Volunteer Blood Donors
NCT00001982
Dynamic Changes of Serum HBV RNA in Chronic Hepatitis B Patients
NCT05991531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
HIV-hepatitis coinfection is problematic in that HIV patients are currently living longer on highly active antiretroviral therapy (HAART). Those who are coinfected with HBV and/or HCV progress more rapidly to cirrhosis and hepatic failure. Further research on the epidemiology, optimal screening and new therapeutic approaches in persons with advanced liver disease, in the setting of effective treatment for viral hepatitis is needed.
The primary objective of the proposed study is to characterize viral liver disease and factors affecting the natural history of viral liver disease in persons with and without HIV with an emphasis on those living in the Washington DC metropolitan area. The cohort will be designed to study research questions with respect to liver disease, disease pathogenesis using genomics, proteomics, and immunologic disease models. Secondary objectives include study of the immunopathogenesis of HBV and HCV disease progression in HIV infected subjects. In addition, this is an invaluable opportunity to determine the prevalence and risk factors associated with the development of hepatocellular carcinoma, the longterm effects of HCV clearance with DAAs, along with biomarker profile(s) for diagnosis and outcome. Moreover, this will serve as a catchment protocol to select appropriate participants for novel HBV and HCV therapeutic trials.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HBV and HCV Co-infection
HBV and HCV Co-infection
No interventions assigned to this group
Hepatitis B
Hepatitis B alone
No interventions assigned to this group
Hepatitis C
Hepatitis C alone
No interventions assigned to this group
HIV and HBV and HCV Tri-Infection
HIV and HBV and HCV Tri-Infection
No interventions assigned to this group
HIV and HBV Co-infection
HIV and HBV Co-infection
No interventions assigned to this group
HIV/HCV Co-Infection
HIV and HCV Co-infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be greater than or equal to 18 years old
2. HBV-infected and/or HCV-infected, or was HCV-infected and successfully treated
3. Willing to undergo genetic testing
4. Willingness to allow study staff to review your medical records between research visits
5. Willing to have samples stored for future research
6. Must have an identifiable primary care physician
7. Willing to undergo HIV testing
8. Childbearing female must test negative for pregnancy
An HBV infected individual is defined as any individual with documentation of the following:
\- Positive Hepatitis B surface antigen within the past 12 months or HBV DNA positive, or prior documentation if the individual is currently on active therapy
An HCV infected individual is defined as any individual with documentation of the following in the past:
\- Positive HCV antibody and/or positive HCV RNA test (HCV RNA of 2,000 IU/mL or greater)
An HIV infected individual is defined as any individual with documentation of the following:
\- Positive Enzyme Linked Immunosorbent Assay followed by a positive Western Blot or detectable HIV viral load or HIV viral less than 50 copies/mL with documentation this individuals is curently on an active HIV antiretroviral regimen.
Exclusion Criteria
1. Unable to comply with research study visits
2. Poor venous access
3. Have any condition that the investigator considers a contraindication to study participation.
4. Childbearing female with positive pregnancy test
Co-enrollment Guidelines: Participants may be enrolled in other protocols as long as the amount of research blood drawn does not exceed the acceptable NIH guidelines.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington D.C. Veterans Affairs Medical Center
FED
National Institutes of Health Clinical Center (CC)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Colleen M Hadigan, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institutes of Health Clinical Center (CC)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Medical Center, Washington D.C.
Washington D.C., District of Columbia, United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190. No abstract available.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004 Mar;11(2):97-107. doi: 10.1046/j.1365-2893.2003.00487.x.
Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6-9. doi: 10.1016/j.jhep.2005.11.004. Epub 2005 Nov 21.
Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. Antivir Ther. 2019;24(4):451-457. doi: 10.3851/IMP3327.
Chaudhury CS, Mee T, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Stanley TL, Hadigan C. Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance. Clin Infect Dis. 2019 Aug 1;69(4):571-576. doi: 10.1093/cid/ciy965.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-CC-0152
Identifier Type: -
Identifier Source: secondary_id
110152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.